MoonLake Immunotherapeutics Class A (MLTX)

MoonLake Immunotherapeutics' stock price experienced significant volatility in the past six months. In late September 2025, the stock plummeted due to disappointing Phase 3 trial results for sonelokimab in hidradenitis suppurativa. In early January 2026, the stock surged due to positive feedback from the FDA regarding the Biologics License Application for sonelokimab.

Information regarding the demand seasonality for MoonLake Immunotherapeutics' products and services is not available. As a clinical-stage biotechnology company, the concept of demand seasonality does not directly apply at this stage.

MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology company focused on developing immunomodulatory therapies for autoimmune and inflammatory diseases. Their primary product candidate, Sonelokimab (SLK), is a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, key drivers of inflammation. Sonelokimab is being evaluated for various inflammatory conditions. The company leverages Nanobody technology, offering potential advantages over traditional antibodies.

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and is domiciled in the Cayman Islands. The company also maintains offices in the UK and Portugal.

MoonLake Immunotherapeutics' brand reputation was significantly impacted in late September 2025 due to disappointing Phase 3 trial results, leading to a stock price crash and securities class action lawsuits. In early January 2026, the company's reputation saw a positive shift following favorable feedback from the FDA, helping the stock recover and generating renewed momentum.

MoonLake Immunotherapeutics' ownership includes institutional, insider, and retail investors. Institutional investors hold a significant portion of the stock. Major institutional shareholders include Bvf Inc/il, Avoro Capital Advisors LLC, and Cormorant Asset Management, LP. Bihua Chen is the largest individual shareholder. Insiders collectively own approximately 9.82% to 40% of the company's stock, while retail investors hold around 6.13% to 88.76%.